Teva CEO on decimated share price: "It's rational enough from a market point of view"
As the CEO of Israeli pharmaceutical company Teva, Kåre Schultz has some work ahead of him in order to convince the market there's light at the end of the tunnel.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
There's no reason to be bitter about the plummeting share price of Israeli pharmaceutical company Teva, as it makes sense, according to CEO Kåre Schultz, who has not yet managed to generate value for the firm's hard-pressed shareholders.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
